Publications

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). by Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK and Mendes RE. published in J. Chemother. 2019; 13: 1-7

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). by Sader HS, Castanheira M, Arends SJR, Goossens H and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (6): 1595-1606

Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents when tested against gram-negative bacterial strains using time-kill curves. by Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ and Shortridge D. published in Antimicrob. Agents Chemother. 2019; 63 (5): e02549

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. by Carvalhaes CG, Castanheira M, Sader HS, Flamm RK and Shortridge D. Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 93-102

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. by Castanheira M, Davis AP, Serio AW, Krause KM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 73-77.

Characterization of beta-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 REPRISE trial for ceftazidime-avibactam: Correlation of efficacy against beta-Lactamase producers. By Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK. Antimicrob. Agents Chemother. 63 (6): e02655, 2019.

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2017-2018). Lead author: HS Sader, presented at ATS 2019, May 17-22, Dallas, Texas, USA
#8470

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2778

Evaluation of the Staphylococcus aureus Analysis “1928D” Pipeline to Determine the Epidemiological Threshold Using Whole Genome Sequence Data. Lead author: LM Deshpande, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2686

Azole Resistance in Candida parapsilosis and Candida tropicalis from a Global Surveillance is Mainly Caused by Alterations in Erg11 and MDR1 Overexpression. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2162

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2783

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae. Lead author: LR Duncan, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2787

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1847

Antimicrobial Activity of Plazomicin Tested against Enterobacteriaceae Isolates from European Medical Centres Stratified by Infection Type (2014-2017). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1873

Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1843

Plazomicin Activity against Enterobacteriaceae Isolates Carrying Genes Encoding Extended-Spectrum β-Lactamases, Carbapenemases, and/or Aminoglycoside-Modifying Enzymes. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1872

Activity of Tedizolid and Comparators against Enterococcus spp. that Include Multidrug-Resistant Clinical Isolates from European and US Medical Centres (2016-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1883

In Vitro Activity of Omadacycline and Comparators against Recent Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1876

Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1882

In Vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecularly Characterized β-Lactamase Genes. Lead author: RE Mendes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1180

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1171

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1170

Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America in 2015-2016. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1199

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1191

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1174

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1172

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1189

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#L0041

In vitro activity of tedizolid against gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014-2016. by Bensaci M, Tan C, Pfaller MA and Mendes RE published in Journal Infect Diseases and Treatment. 2018; 4 (1): 2

In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories. by Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL and Castanheira M published in Antimicrob Agents Chemother. 2018; 62 (10): e01230

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016). by Duncan LR, flamm RK, Sader HS and Mendes RE published in Diagn. Microbiol. Infect. Dis.: in press, 2018.

Trends in Antimicrobial Nonsusceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1444

Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam In Vitro Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#2427

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates. Lead author: D Shortridge, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2373

Activity of a Long-Acting Echinocandin Rezafungin Tested against Invasive Fungal Isolates Collected Worldwide. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2400

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1081

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1345

Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1364

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Patients with Pneumonia in US Medical Centers. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1485

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1523

Omadacycline In Vitro Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1377

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected from Bloodstream Infections in the United States from 2015-2017. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1047

Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader, presented at ID Week 2018, October 3-7, San Francisco, CA, USA.
#1000

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#1004

Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying bla_kpc-2 reveals a heterogenous population and reversible genotype. by Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA and MacVane SH published in MSphere. 2018; 3 (5): e00408

Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. Antimicrob. Agents Chemother.: in press, 2018.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. by Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M and Jain R. published in Infect Drug Resist. 2018; 2018 (11): 1499-1510

Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. by Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM and Flamm RK. published in J. Antimicrob. Chemother.: in press, 2018.